Medical Cannabis for Multiple Sclerosis in the UK

Multiple Sclerosis and the Case for Cannabis

Multiple sclerosis (MS) is a chronic neurological condition in which the immune system attacks the myelin sheath surrounding nerve fibres in the brain and spinal cord. It affects over 130,000 people in the UK, making it one of the most common neurological conditions in the country. Symptoms vary widely but often include muscle spasticity, chronic pain, fatigue, bladder dysfunction, and cognitive difficulties.

For many MS patients, spasticity — the involuntary stiffening and spasming of muscles — is one of the most debilitating symptoms. It can severely limit mobility, disrupt sleep, and cause significant pain. Conventional antispasticity drugs such as baclofen and tizanidine are not effective for all patients and can cause drowsiness and weakness.

It is in this context that cannabis-based medicines have attracted particular attention in the MS community.

Sativex: The Licensed Cannabis Medicine for MS

The UK is one of the few countries in the world where a licensed cannabis-based medicine specifically for MS spasticity is available: Sativex (nabiximols). Sativex is an oromucosal spray containing a 1:1 ratio of THC and CBD, derived from cannabis plants. It is licensed in the UK for the treatment of moderate to severe spasticity in adults with MS who have not responded adequately to other antispasticity medications.

Sativex can be prescribed on the NHS by specialist neurologists, though access varies significantly by region due to NICE guidance and local commissioning decisions. Many MS patients find that they are unable to access Sativex through the NHS and instead seek private prescriptions for other cannabis-based medicinal products.

Private Prescriptions for MS

Beyond Sativex, a range of unlicensed cannabis-based medicinal products — including cannabis oils and dried flower — can be prescribed privately by specialist doctors for MS patients. These products may be appropriate for patients who do not respond to Sativex, who prefer a different formulation, or who cannot access Sativex through the NHS.

The MS Society and MS-UK both provide guidance on accessing medicinal cannabis for MS. The key eligibility criteria for a private CBMP prescription typically include a confirmed MS diagnosis and evidence that conventional treatments have not provided adequate spasticity control.

What Does the Evidence Show?

The evidence base for cannabis in MS is among the strongest of any condition. Multiple randomised controlled trials and real-world registry studies have demonstrated that cannabinoids can reduce spasticity scores, improve sleep, and reduce pain in MS patients. The UK Medical Cannabis Registry has published data showing improvements in spasticity-related quality of life in MS patients prescribed CBMPs.

A 2024 review in the Cochrane Database of Systematic Reviews concluded that cannabis-based medicines probably reduce patient-reported spasticity in MS, with a moderate quality of evidence. The review also noted improvements in pain and sleep.

Practical Considerations for MS Patients

If you are an MS patient considering medical cannabis, there are several practical points to bear in mind. First, discuss your interest with your neurologist, as they may be able to prescribe Sativex on the NHS or refer you to a specialist clinic. Second, if pursuing a private prescription, ensure you work with a GMC-registered specialist doctor who has experience in prescribing CBMPs for neurological conditions. Third, keep your GP informed of any new prescriptions.

CPGUK can help you navigate this process. Our free patient support service can connect you with specialist clinics and provide guidance on accessing medical cannabis for MS in the UK.